Electrochemotherapy with cisplatin in the treatment of tumor cells resistant to cisplatin

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4463-4466

  Cemazar, Maja ^a   Sersa, Gregor ^a   Miklavcic, Damijan ^b  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cisplatin resistance; Electrochemotherapy; Electroporation; Ovarian carcinoma

Indexed keywords

CISPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ELECTROCHEMOTHERAPY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL;

CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CISPLATIN; CLONE CELLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032436818     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Haskell CM: Drugs used in cancer chemotherapy. In: Cancer treatment (Haskell CM, ed) WB Saunders Company, 1990, pp 55-57.
2. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990.
3. Timmer-Bosscha H, Mulder NH and de Vries EGE: Modulation of Cis- diamminedichloroplatinum (II) resistance: a review. Br J Cancer 66: 227-238, 1992.
4. Jekunen AP, Shalinsky DR, Hom DK, Albright KD, Heath D and Howell SB: Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro. Biochem Pharmacol 45: 2079-2085, 1993.
5. Beketic-Oreskovic L, Jaksic M, Oreskovic S and Osmak M: Hyperthermic modulation of resistance to cis-diamminedichloroplatinum (II) in human larynx carcinoma cells. Int J Hyperthermia 13: 205-214, 1997.
6. Marverti G, Andrews PA, Piccinini G, Ghiaroni S, Barbieri D and Moruzzi MS: Modulation of cis-diamminedichloroplatinum (II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. Eur J Cancer 33: 669-675, 1997.
7. Sersa G, Cemazar M and Miklavcic D: Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 55: 3450-3455, 1995.
8. Čemažar M, Miklavcic D, Vodovnik L, Jarm T, Rudolf Z, Stabuc B, Cufer T and Sersa G: Improved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in mice. Radiol Oncol 29: 121-127, 1995.
9. Cemazar M, Milacic R, Miklavcic D, Dolzan V and Sersa G: Intratumoral cisplatin administration in electrochemotherapy: Antitumor effectiveness, sequence dependence and platinum content. Anti-Cancer Drugs 19: 525-530, 1998.
10. Sersa G, Miklavcic D, Čemažar M, Belehradek J Jr, Jarm T and Mir LM: Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient mice. Bioelectroch Bioener 43: 279-283, 1997.
11. Melvik JE, Pettersen EO, Gordon PB and Selgen PO: Increase in cis-Dichlorodiammineplatinum(II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells. Eur J Cancer Clin Oncol 22: 1523-1530, 1986.
12. Sersa G, Stabuc B, Čemažar M, Jancar B, Miklavcic D and Rudolf Z: Electrochemotherapy with cisplatin: Potentiation of local cisplatin antitumor effectiveness by application of electric pulses in cancer patients. Eur J Cancer 34: 1213-1218 1998.
13. Čemažar M, Jarm T, Miklavcic D, Lebar Macek A, Kopitar NA, Ihan A, Sersa G: Effects of electric field intensity on electropermabilization and electrosensitivity of various tumor cells lines in vitro. Electro Magnetobiol 17: 261-270, 1998.
14. Howell SB, Vick J, Andrews PA, Velury S and Sanga S: Dipyridamole: biochemical modulation of cisplatin. In: Proceedings of the fifth international symposium on platinum and other metal coordination compounds in cancer chemotherapy (Marino N, ed). Martinus Nijhoff Publishing; Padua, Italy, pp 228-234.
15. Mann SC, Anderws PA, Howell SB: Modulation of cis-diamminedichloroplatinum (II) accumulation and sensitivity by forskolin and 3-isobytil-1-methybcantine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 49: 2674-2678, 1991.
16. Orlowski S and Mir LM: Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1154: 51-63, 1993.
17. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E and Riou G: Characterization of a human ovarian adenocarcinoma line, IGROV 1, in tissue culture and in nude mice. Cancer Res 45: 4970-4979, 1985.
18. Fajac A, Da Silva J, Ahomadegbe JC, rateau JG, Bernaudin JF, Riou G and Benard J: Cisplatin-induced apoptosis and p53 gene status in a cisplatin resistant human ovarian carcinoma cell line. Int J Cancer 68: 67-74, 1996.